Is my portfolio
One Report to Answer all your Questions!
Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
902.15
10.60 (1.19%) Cadila Healthcare informs about press release
Date: 23-02-2022Cadila Healthcare has informed that it enclosed a copy of press release dated February 23, 2022 titled ‘Zydus receives final approval from USFDA for Dapagliflozin Tablets’.
The above information is a part of company’s filings submitted to BSE.